Related Experiment Video
Updated: Aug 13, 2026

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
Published on: April 19, 2019
Hypertension optimal treatment: the Israeli HOT Study Group. Hypertension Optimal Treatment
1Chorley Institute of Hypertension, Chaim Sheba Medical Center, Israel.
Insights
The Hypertension Optimal Treatment (HOT) Study found felodipine effective for managing hypertension. Most Israeli patients tolerated the treatment well, enabling continued use in this hypertensive cohort.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Hypertension is a major risk factor for cardiovascular disease.
- Effective blood pressure control is crucial for reducing morbidity and mortality.
- The Hypertension Optimal Treatment (HOT) Study investigated different diastolic blood pressure targets.
Purpose of the Study:
- To assess the cardiovascular effects of three target diastolic blood pressure levels (< 90, < 85, and < 80 mm Hg) in hypertensive patients.
- To evaluate the efficacy and tolerability of felodipine treatment in the Israeli cohort of the HOT Study.
- To compare treatment patterns in the Israeli cohort with the global HOT Study population.
Main Methods:
- Recruitment of 411 patients in the Israeli cohort of the multinational HOT Study.
- Initial treatment with felodipine, supplemented with other antihypertensive drugs as needed.
- Comparison of treatment outcomes and drug dosages between Israeli patients and those from other countries.
Main Results:
- Israeli patients had a higher rate of prior antihypertensive treatment, indicating a more complex patient profile.
- A lower percentage of Israeli patients received low-dose felodipine (50% vs. 56% globally).
- A higher percentage of Israeli patients required high-dose felodipine plus additional medications (3.8% vs. 2.9% globally).
- Felodipine demonstrated good tolerability, allowing most patients to continue the regimen.
Conclusions:
- Felodipine is well-tolerated and effective in managing hypertension in the Israeli cohort.
- Treatment strategies were adjusted in Israeli patients due to higher prevalence of prior treatments.
- The HOT Study provides valuable insights into optimizing antihypertensive therapy for diverse patient populations.
Abstract:
A total of 411 patients were recruited in the Israeli cohort of the Hypertension Optimal Treatment (HOT) Study, a multinational study conducted to assess the effect on cardiovascular morbidity and mortality in hypertensive patients of three levels of target diastolic blood pressure: < 90, < 85, and < 80 mm Hg. Initial treatment with felodipine in all patients was supplemented with other drugs as needed. When compared to the subjects in the rest of the world, the percentage of Israeli patients getting previous antihypertensive treatment was higher, reflecting a higher proportion of hospital-recruited patients. This accounted for the lower percentage of Israeli patients ending up with low-dose felodipine: 50% vs 56% in other countries. The percentage of patients getting high-dose felodipine plus additional drugs was also higher: 3.8% vs 2.9% for other countries. Felodipine was remarkably well tolerated, and most of the patients were able to continue this drug regimen.
More Related Videos
Related Concept Videos
Hypertension and Regulation of Blood Pressure
Hypertension I: Introduction
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension V: Nursing Management

